Ebola Virus Vaccine Market Size & Share 2023 – 2032
Market Size by Strain Type (Vesicular Stomatitis Virus (rVSV), Adeno Virus Serotype, 26), End Use (Hospitals, Clinics.
Report ID: GMI6083
|
Published Date: June 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Ebola Virus Vaccine Market Size
Ebola Virus Vaccine Market size accounted for USD 4.4 million in 2022 and is estimated to grow at 32.6% to reach USD 71 million by 2032. The growing incidence of zoonotic diseases across the globe will drive the market expansion.
Ebola Virus Vaccine Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
For instance, in 2020, according to the World Health Organization (WHO), around 60% of known infectious diseases and over 75% of emerging infectious diseases are zoonotic in origin. Thus, increasing incidence of zoonotic disease such as Ebola and zoonotic influenza among others is expected to boost the market progression. Furthermore, increasing public health initiatives to prevent and control Ebola outbreaks have resulted in increased investments in vaccine development and procurement, thereby fostering the market trends.
Ebola virus vaccines are developed using various approaches, such as viral vectors, recombinant proteins and DNA-based platforms. These vaccines typically contain components of the Ebola virus such as viral proteins or genetic material that are modified or attenuated to be safe for use in humans. When administered, the vaccine triggers an immune response that produces specific antibodies and cellular immunity, providing protection against the Ebola virus.
COVID-19 Impact
The COVID-19 pandemic had a significant impact on the Ebola virus vaccine market. Increasing number of COVID-19 cases lead to a shift in focus from developing Ebola vaccines to COVID-19 vaccines. The COVID-19 pandemic and emergence of new variants of the SARS-CoV-2 virus have created the urge of developing COVID-19 vaccine to limit and curb the spread of COVID-19 infection. Thus, owing to such aforementioned factor, a temporary shift shit from addressing Ebola vaccine development was observed, thereby potentially impacted the progress and effectiveness of Ebola vaccine development programs during the period.
Ebola Virus Vaccine Market Trends
Increasing research and development efforts for Ebola virus vaccine development is expected to significantly driver the market growth. Various pharmaceutical companies, research institutions and organizations are investing in R&D activities to advance the development of effective vaccines against infectious diseases including Ebola. For instance, in 2021, Bavarian Nordic and Johnson & Johnson partnered to support efforts by the World Health Organization (WHO) to prevent further spread of Ebola in West Africa through the donation of up to 200,000 courses of the Johnson & Johnson Ebola vaccine regimen. Thus, the growing demand to prevent the spread of Ebola in West African countries is expected to drive the market growth.
Ebola Virus Vaccine Market Restraint
Stringent regulatory approval of Ebola virus vaccines can significantly hinder the market growth. The complex and rigorous regulatory requirements leads to delay the introduction of new vaccines and limit the entry of new players into the market. Also, increase in approval time and costs associated with vaccine development and commercialization will further hinder the market growth. Furthermore, compliance with stringent regulations necessitates extensive clinical trials, safety evaluations, and manufacturing standards can pose challenges for small scale companies with limited resources. These regulatory hurdles can slow down innovation, limit competition and ultimately restrict the commercialization and availability of Ebola virus vaccines, thereby hampering the market growth.
Ebola Virus Vaccine Market Analysis
By strain type, the Ebola virus vaccine market is classified into vesicular stomatitis virus (rVSV) and adeno virus stereotype - 26. The vesicular stomatitis virus (rVSV) segment accounted for 53.9% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Ebola virus vaccines utilizing the vesicular stomatitis virus (rVSV) strain have shown promising results in the Ebola vaccine market. The rVSV strain serves as a vector to deliver specific Ebola virus antigens, triggering an immune response in vaccinated individuals. This approach offers several advantages including rapid production capabilities, scalability and the potential for single-dose administration. Moreover, the established safety profile of the rVSV strain makes its more suitable for developing other Ebola virus vaccines. Thus, the aforementioned factors significantly contributed to the market growth.
The end-use in Ebola virus vaccine market is categorized into hospitals, clinics, ambulatory surgical centers and other end-users. Hospitals segment accounted for USD 1.6 million market revenue in 2022. Availability of skilled medical professionals and advanced healthcare infrastructure has propelled the hospitals & clinics segment growth. Also, hospitals offer accessibility and convenience for individuals seeking vaccination during their regular visits for healthcare needs. Furthermore, developed infrastructure and well-established storage facilities contributes to streamlined operations and reduces the risk of vaccine shortage as well as wastage in the hospital & clinics. Thus, the aforementioned factors is expected to drive the market growth.
U.S. Ebola virus vaccine market accounted for over 52.3% market share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. The increasing prevalence of zoonotic diseases and rising adoption of advanced medical technologies is expected to boost the regional market growth. Also, presence of well-established healthcare infrastructure, key market players and research activities contribute to the growth of Ebola vaccine research & development. Further, growing demand for preventive healthcare, rising government investments to create awareness regarding vaccination and controlling outbreaks will further supplement the expansion of Ebola vaccine market growth in the North America region.
Ebola Virus Vaccine Market Share
Major market players operating in the Ebola virus vaccine industry include
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section include both companies that have commercial drug available in market as well as those that are into clinical phase development.
Ebola Virus Vaccine Industry News:
The Ebola virus vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Strain Type
End-use
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →